Vonoprazan as a Long-term Maintenance Treatment for Erosive Esophagitis: VISION, a 5-Year, Randomized, Open-label Study
Clinical Gastroenterology and Hepatology · 2025-04 · 23 (5) · 748-757.e5
DOI: 10.1016/j.cgh.2024.08.004 ↗Kurz gefasst
Klinische Studie (Phase IV) in der Zeitschrift Clinical Gastroenterology and Hepatology, 2025-04. Verfasst von Naomi Uemura und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, National Center for Global Health and Medicine, Kohnodai Hospital, Ichikawa, Chiba, Japan. Hauptthemen laut MEDLINE: Esophagitis, Maintenance Chemotherapy, Pyrroles, Sulfonamides. Die Arbeit wurde bisher 56-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: EA Pharma Co., Ltd., Takeda Pharmaceutical Company.
Abstract (Originalsprache)
BACKGROUND & AIMS: Acid secretion inhibitors are associated with hypergastrinemia, which can lead to gastric mucosal changes. Potassium-competitive acid blockers, such as vonoprazan, are more potent than proton pump inhibitors, but long-term safety data are lacking. METHODS: In this phase IV, randomized trial, patients with erosive esophagitis (EE) received induction therapy (once daily vonoprazan 20 mg or lansoprazole 30 mg; ≤8 weeks). Those with healed EE received maintenance therapy (once daily vonoprazan 10 mg or lansoprazole 15 mg) for 260 weeks (2:1). The primary endpoint was the proportion of patients with malignant epithelial cell alterations, parietal cell hyperplasia, foveolar hyperplasia, enterochromaffin-like (ECL) cell hyperplasia, and G-cell hyperplasia. RESULTS: Overall, 202/208 patients (vonoprazan, n = 139; lansoprazole, n = 69) achieved healed EE and received maintenance therapy. No malignant alterations or gastric neuroendocrine tumors (NETs) were observed; there was 1 adenoma in each group. At week 260, significantly more patients taking vonoprazan vs lansoprazole had parietal cell hyperplasia (97.1% vs 86.5%) and foveolar hyperplasia (14.7% vs 1.9%); proportions of patients with ECL cell hyperplasia (4.9% vs 7.7%) and G-cell hyperplasia (85.3% vs 76.9%) were similar. Median serum gastrin levels were higher with vonoprazan treatment vs lansoprazole (625 pg/mL vs 200 pg/mL). Incidences of adverse events were comparable for both treatments. CONCLUSIONS: The exploratory VISION study assessed the safety profile of vonoprazan and lansoprazole over 5 years in Japanese patients with healed EE. Although gastrin concentration, parietal cell hyperplasia, and foveolar hyperplasia were higher in the vonoprazan group, there was no increased risk of malignant epithelial cell alterations and gastric NETs. (ClinicalTrials.gov, NCT02679508).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, National Center for Global Health and Medicine, Kohnodai Hospital, Ichikawa, Chiba, Japan.
- General Internal Medicine, Hyogo Prefectural Harima-Himeji General Medical Center, Himeji, Hyogo, Japan.
- Department of General Internal Medicine 2, Kawasaki Medical School General Medical Center, Okayama, Japan.
- Department of Clinical Laboratory Medicine, Shiga University of Medical Science Hospital, Otsu, Shiga, Japan.
- Department of Human Pathology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
- Department of Gastroenterology and Hepatology, National Center for Global Health and Medicine, Tokyo, Japan.
Förderung
- EA Pharma Co., Ltd.
- Takeda Pharmaceutical Company
Zitieren
APA
Uemura, N., Kinoshita, Y., Haruma, K., Kushima, R., Yao, T., Akiyama, J., Aoyama, N., Baba, Y., Suzuki, C., & Ishiguro, K. (2025). Vonoprazan as a Long-term Maintenance Treatment for Erosive Esophagitis: VISION, a 5-Year, Randomized, Open-label Study. Clinical Gastroenterology and Hepatology, 23(5), 748-757.e5. https://doi.org/10.1016/j.cgh.2024.08.004
Vancouver
Uemura N, Kinoshita Y, Haruma K, Kushima R, Yao T, Akiyama J, et al. Vonoprazan as a Long-term Maintenance Treatment for Erosive Esophagitis: VISION, a 5-Year, Randomized, Open-label Study. Clinical Gastroenterology and Hepatology. 2025;23(5):748-757.e5. doi:10.1016/j.cgh.2024.08.004
BibTeX
@article{Uemura2025,
author = {Uemura, Naomi and Kinoshita, Yoshikazu and Haruma, Ken and Kushima, Ryoji and Yao, Takashi and Akiyama, Junichi and Aoyama, Nobuo and Baba, Yuji and Suzuki, Chihiro and Ishiguro, Kaori},
title = {Vonoprazan as a Long-term Maintenance Treatment for Erosive Esophagitis: VISION, a 5-Year, Randomized, Open-label Study},
journal = {Clinical Gastroenterology and Hepatology},
year = {2025},
volume = {23},
number = {5},
pages = {748--757.e5},
doi = {10.1016/j.cgh.2024.08.004}
}
EUVIMED